Skip to main content

Zyomyx Sells Protein Profiling Biochip System to Aventis

NEW YORK, March 6 - Zyomyx today said that Aventis has agreed to buy one of its Protein Profiling Biochip systems.

The tool consists of Zyomyx's first protein profiling biochip--called the Human Cytokine Biochip--as well as the Assay 1200 automated workstation and the Scanner 100 reader and data-analysis software.

Zyomyx said Aventis will apply the Protein Profiling Biochip System and Human Cytokine Biochips to its R&D programs in inflammation.

Financial details were not disclosed.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.